Sulfa Resistance and Dihydropteroate Synthase Mutants in Recurrent Pneumocystis carinii Pneumonia

Aimable Nahimana,*1 Meja Rabodonirina,† Jannik Helweg-Larsen,‡ Isabelle Meneau,* Patrick Francioli,* Jacques Bille,* and Philippe M. Hauser*

Failure of sulfa or sulfone prophylaxis is associated with mutations in Pneumocystis carinii gene coding for dihydropteroate synthase (DHPS). The DHPS genotype was analyzed in AIDS patients who had two separate episodes of P. carinii pneumonia. The results suggest that DHPS mutations can be selected de novo within patients by the pressure of a sulfa or sulfone drug.

Cotrimoxazole, the antifolate drug combination of trimethoprim and sulfamethoxazole, is the drug of choice for the prophylaxis and treatment of Pneumocystis carinii pneumonia (PCP), a life-threatening disease in immunosuppressed patients. Trimethoprim is an inhibitor of dihydrofolate reductase, whereas sulfamethoxazole inhibits dihydropteroate synthase (DHPS). The antipneumocystis activity is believed to be due mainly to sulfamethoxazole (1). Dapsone is a sulfone drug, also frequently used, that targets DHPS. Widespread use of sulfa and sulfone drugs to prevent and treat PCP in recent years has correlated with an increase of the prevalence of mutations in the gene coding for DHPS (2,3). The most frequent DHPS mutations occur at nucleotide positions 165 and 171, which lead to an amino acid change at positions 55 (Thr to Ala) and 57 (Pro to Ser). These mutations are located in the sulfa-binding site and may appear as either a single or double mutation in the same isolate. Similar mutations in other microbial pathogens confer sulfa resistance (4,5). In P. carinii, DHPS mutations are associated with failure of sulfa or sulfone prophylaxis (1,6) and decreased survival of the patient at 3 months after PCP (2). However, patients harboring P. carinii types with DHPS mutations are most often successfully treated with high-dose cotrimoxazole (6). Because a standardized culture system for P. carinii does not exist, the level of sulfa resistance conferred by these mutations cannot be determined with in vitro susceptibility tests. A key issue is whether the recent emergence of DHPS mutations is a result of P. carinii transmission between patients or arises from selection within patients by the pressure of a sulfa or sulfone drug, two possibilities that are not mutually exclusive. To investigate the latter possibility, we analyzed patients who had had two separate episodes of PCP.

The Study

P. carinii DNA was extracted from bronchoalveolar lavage specimens by using the Qiamp Blood Kit (QIA-GEN GmbH, Hilden, Germany). Bronchoalveolar lavage specimens from 13 patients with recurrent PCP episodes were collected from four European hospitals (Lyon, France; Copenhagen, Denmark; Lausanne, Switzerland; and La Chaux-de-Fonds, Switzerland). To determine the prevalence of the different P. carinii molecular types, we analyzed bronchoalveolar lavage specimens from 310 PCP patients from two Swiss hospitals (Lausanne, 111 patients; Zurich, 64 patients) and Lyon’s hospital (135 patients). Specific information on demographic and clinical characteristics, chemoprophylaxis, and treatment regimens were obtained from the medical charts. P. carinii infecting humans (now named P. jiroveci [7]) was typed by using the multilocus method developed in our laboratory as previously described (8–10). In this method, four variable regions of the P. carinii genome are amplified by polymerase chain reaction (PCR), followed by the detection of polymorphisms using single-strand conformation polymorphism (SSCP). A P. carinii type is defined by a combination of four alleles corresponding to the four genomic regions. If a specimen harbored two alleles of one or more of the four genomic regions, the patient was considered to be co-infected with two or more P. carinii types (9). This typing system has been validated and the stability of its markers assessed; its index of discriminatory power has been estimated to be 0.93 (10). The full length of the DHPS gene was amplified by PCR as described previously (1). PCR products (765 bp) were cloned, and both strands were sequenced (5 clones per sample). The five clones had identical sequences for all samples, except for those from patients 3 and 4, which contained a mixture of DHPS sequences.

1Aimable Nahimana contributed to the design of the study, analyzed the samples by polymerase chain reaction and DNA sequencing, and wrote the draft of the manuscript. Meja Rabodonirina and Jannik Helweg-Larsen reviewed medical charts and provided bronchoalveolar lavage specimens. All authors contributed to the analysis of data and writing of the paper. Philippe M. Hauser initiated and supervised all aspects of the study.
Thirteen patients with two separate PCP episodes were analyzed (Table). All patients had recovered between episodes. The intervals between the episodes ranged from 4 to 25 months. All patients had AIDS and all, except patients 8 and 9, were men, with a median age of 35 (range 23–51) and median CD4 cell count of 9.5 cells/µL (range 0–98). Some patients were co-infected with two different *P. carinii* types, as shown by PCR-SSCP multilocus typing method (patients 4, 5, 8, 11, and 13) or DHPS genotyping (patients 3 and 4). In seven (54%) patients (patients 1–7), the same PCR-SSCP type was observed in both episodes of PCP; six (46%) patients (patients 8–13) had different types in the first and second episodes. This rate of genotype switch is similar to that reported in previous studies, in which such a change was observed in approximately half of recurrent episodes (11–14). The importance of a genotype switch remains uncertain. Indeed, the switch might be due to a de novo infection or to the reactivation of a genotype not detected in the first episode because of the compartmentalization of different co-infecting *P. carinii* types in the lungs (15).

A second episode of PCP could result either from reactivation of organisms that caused the first episode or from de novo infection with a new *P. carinii* type acquired from an exogenous source. In seven patients (patients 1–7), reactivation was strongly suggested by the detection of identical SSCP types in both episodes of PCP. An alternative explanation could be de novo infection in the second episode by the same *P. carinii* PCR-SSCP type as that which caused the first episode. However, the prevalence of the types observed in the seven “reactivation” cases was low in Lyon and Switzerland during the study period (types no. 2, 5, and 7 represented 7%, 6%, and 10%, respectively, of Lyon’s isolates; type 6 represented only 3.5% of the Swiss isolates [Figure]). Thus, reinfection with these specific types was unlikely. All Danish patients (1, 3, and 6) were infected with type 6. Although no prevalence data for SSCP genotypes in Denmark are available, no indication of possible contact between these patients, over-

**Table. Pneumocystis carinii DHPS and PCR-SSCP genotyping in AIDS patients with recurrent pneumonia**

<table>
<thead>
<tr>
<th>Patient no.</th>
<th>Cityb</th>
<th>Age</th>
<th>Date of episode 1/2</th>
<th>CD4/mm³</th>
<th>Prophylaxis at PCP episodec</th>
<th>Treatment</th>
<th>Outcome of treatment</th>
<th>P. carinii PCR-SSCP type</th>
<th>DHPS genotyped</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Co</td>
<td>29</td>
<td>7/16/1993</td>
<td>9</td>
<td>D</td>
<td>CO → P⁹</td>
<td>Success</td>
<td>6</td>
<td>WT</td>
</tr>
<tr>
<td>2</td>
<td>Ly</td>
<td>36</td>
<td>1/31/1994</td>
<td>58</td>
<td>D</td>
<td>A</td>
<td>Success</td>
<td>7</td>
<td>M2</td>
</tr>
<tr>
<td>3</td>
<td>Co</td>
<td>51</td>
<td>8/19/1994</td>
<td>0</td>
<td>No</td>
<td>CO → C/P⁸</td>
<td>Success</td>
<td>6</td>
<td>WT/M1</td>
</tr>
<tr>
<td>4</td>
<td>Ly</td>
<td>32</td>
<td>11/23/1997</td>
<td>75</td>
<td>No</td>
<td>CO</td>
<td>Success</td>
<td>2, 5</td>
<td>WT/M3</td>
</tr>
<tr>
<td>5</td>
<td>Ly</td>
<td>28</td>
<td>4/19/1995</td>
<td>70</td>
<td>No</td>
<td>A</td>
<td>Success</td>
<td>7, 8</td>
<td>WT</td>
</tr>
<tr>
<td>6</td>
<td>Co</td>
<td>35</td>
<td>11/16/1995</td>
<td>98</td>
<td>CO</td>
<td>P</td>
<td>Success</td>
<td>6</td>
<td>WT</td>
</tr>
<tr>
<td>7</td>
<td>CF</td>
<td>41</td>
<td>2/3/1998</td>
<td>7</td>
<td>CO</td>
<td>P</td>
<td>Success</td>
<td>6</td>
<td>M3</td>
</tr>
<tr>
<td>8</td>
<td>La</td>
<td>28</td>
<td>11/24/1990</td>
<td>53</td>
<td>No</td>
<td>T</td>
<td>Success</td>
<td>6, 10</td>
<td>WT</td>
</tr>
<tr>
<td>9</td>
<td>Co</td>
<td>25</td>
<td>12/8/1992</td>
<td>18</td>
<td>No</td>
<td>CO</td>
<td>Success</td>
<td>7</td>
<td>WT</td>
</tr>
<tr>
<td>10</td>
<td>Co</td>
<td>35</td>
<td>3/22/1993</td>
<td>10</td>
<td>No</td>
<td>CO → P⁹</td>
<td>Success</td>
<td>18</td>
<td>WT</td>
</tr>
<tr>
<td>11</td>
<td>Ly</td>
<td>23</td>
<td>3/30/1994</td>
<td>22</td>
<td>No</td>
<td>CO → A²</td>
<td>Success</td>
<td>4, 7</td>
<td>M3</td>
</tr>
<tr>
<td>12</td>
<td>Ly</td>
<td>46</td>
<td>9/21/1996</td>
<td>61</td>
<td>No</td>
<td>CO</td>
<td>Success</td>
<td>15</td>
<td>WT</td>
</tr>
<tr>
<td>13</td>
<td>Ly</td>
<td>43</td>
<td>10/12/1994</td>
<td>50</td>
<td>No</td>
<td>CO</td>
<td>Success</td>
<td>1, 2</td>
<td>M2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>3/25/1996</td>
<td>5</td>
<td>PM/SD</td>
<td>P+A</td>
<td>Success</td>
<td>1, 3</td>
<td>M2</td>
</tr>
</tbody>
</table>

**Note:** DHPS, dihydropteroate synthase; PCR, polymerase chain reaction; SSCP, single-strand conformation polymorphism.

1. PCP, *Pneumocystis carinii* pneumonia; DHPS, dihydropteroate synthase; PCR, polymerase chain reaction; SSCP, single-strand conformation polymorphism.
2. Co, Copenhagen (Denmark); CF, La Chaux-de-Fonds (Switzerland); La, Lausanne (Switzerland); Ly, Lyon (France).
3. A, atovaquone; CO, cotrimoxazole; C/P, clindamycin/primaquine; D, dapsone; D+T, dapsone and trimethoprim; P, pentamidine; P+A, pentamidine and atovaquone; PM/SD (pyrimethamine/sulfadiazine inhibitors of dihydrofolate reductase (DHFR) and DHPS, respectively); T, trimetrexate (an inhibitor of DHFR).
4. WT, wild type (Thr55 Pro57); M1, mutant 1 (Ala55 Pro57); M2, mutant 2 (Thr55 Ser57); M3, mutant 3 (Ala55 Ser57 double mutant).
5. Switch of molecules because of toxicity for patients 3, 6, and 11 and because of toxicity and treatment failure for patients 1 and 10.
6. Caused by PCP.
remaining patients (6 and 7), the DHPS selected when drug pressure is exerted. In the two 
estimation (p<0.02, Fisher exact test).

mutant DHPS and second episodes attributable to reactivation (Table). This observation suggests an association between mutant DHPS strains and second episodes caused by reinfection (7/7), compared to only two of six second episodes caused by reinfection (Table). This observation suggests an association between mutant DHPS and second episodes attributable to reactivation (p<0.02, Fisher exact test).


drug pressure in patients with HIV-infection, although the impact of DHPS mutations on retreatment with sulfa or sulfone drugs remains to be determined. De novo selection of P. carinii DHPS strongly favors the hypothesis that P. carinii is developing sulfa and sulfone resistance.

Acknowledgments

We thank R. Lienhard for the samples he kindly provided and S. Picot for storage of the specimens. We also thank A. Telenti for critical reading of the manuscript, as well as J.L. Touraine, D. Peyramond, and C. Trepo for access to patients’ charts in Lyon.

Financial support for this study was provided by the Swiss National Program on AIDS Research grant 3345- 65407, Swiss National Fund for Scientific Research grant 32-56715.99; Centre de Coordination de la Lutte contre les Infections Nosocomiales Sud-Est et Hospices Civils de Lyon; the Swiss Federal Office for Education and Science for participation in EUROCARINII project, Framework V Program, European Commission; and a North-South fellowship from Lausanne University (supporting A.N.).

Dr. Nahimana obtained his bachelor’s degree and master’s degree in microbiology at the University of Lausanne. The present work was submitted by A. Nahimana as partial fulfillment for a PhD degree at the University of Lausanne and was performed under the supervision of P. Hauser.

References


Address for correspondence: Philippe M. Hauser, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland; fax: +41 21 314 40 60; email: Philippe.Hauser@chuv.hospvd.ch